-30.4%
TSLL vs MRNA
+786.1%
-816.4%
-70.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.4% | -7.0% | +10.3% | +4.0% |
| 7D | +33.0% | -4.2% | +37.1% | +33.4% |
| 30D | +7.7% | +7.0% | +0.7% | +7.1% |
| 3M | +34.7% | +263.4% | -228.6% | +15.5% |
| 6M | -31.5% | +334.3% | -365.8% | -45.4% |
| YTD | -42.4% | +684.5% | -726.9% | -56.1% |
| All | -30.4% | +786.1% | -816.4% | -48.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling